RIPK1-IN-21

• UNSPSC Description:

  RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ripk1-in-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(C2(C3)CC3(C#N)C2)N=C4N1[C@@H](CC4)C5=CC(F)=CC(F)=C5

• Molecular Weight:

  328.32

• References & Citations:

  [1]Sabnis R W. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, AutoimmSabnis R W. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases[J]. ACS Medicinal Chemistry Letters, 2024.une, and Inflammatory Diseases[J]. ACS Medicinal Chemistry Letters, 2024.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3016304-64-3